RESUMEN
Mastering nuclear fusion, which is an abundant, safe, and environmentally competitive energy, is a great challenge for humanity. Tokamak represents one of the most promising paths toward controlled fusion. Obtaining a high-performance, steady-state, and long-pulse plasma regime remains a critical issue. Recently, a big breakthrough in steady-state operation was made on the Experimental Advanced Superconducting Tokamak (EAST). A steady-state plasma with a world-record pulse length of 1056 s was obtained, where the density and the divertor peak heat flux were well controlled, with no core impurity accumulation, and a new high-confinement and self-organizing regime (Super I-mode = I-mode + e-ITB) was discovered and demonstrated. These achievements contribute to the integration of fusion plasma technology and physics, which is essential to operate next-step devices.
RESUMEN
OBJECTIVE: To observe the reperfusion rate of acute myocardial infarction (AMI) affected by inspiring nitric oxide (NO) and resolving thrombus through veins. METHODS: Sixty cases with AMI were randomly divided into test group (n=30) and control groups (n=30). Patients in test group were cured with NO (20+/-1)mg/L inspiration for 30 minutes at once before admission and urokinase (150x10(4) U) adding 0.9% sodium chloride intravenously injected within 30 minutes, while patients in control were treated with urokinase as the same method of the test group. RESULTS: The reperfusion and non-reperfusion patients were 25 and 5 cases in test group, and they were 19 and 11 cases in control group. The reperfusion rate of AMI in test group was significantly higher than that in control group 83.3% vs. 63.3% (P<0.05). No peak periods of lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) appeared in test group, and the difference was significant compared to the control group (P<0.05). CONCLUSION: NO inspiration before urokinase is an effective method to treat AMI and advance the reperfusion rate.
